Gordian Capital Singapore Pte Ltd Lowers Stake in Natera, Inc. $NTRA

Key Points

• Gordian Capital Singapore Pte Ltd reduced its stake in Natera, Inc. by 27.8%, now holding 9,450 shares valued at approximately $1.36 million.
• Several institutional investors, including the Canada Pension Plan Investment Board and Parnassus Investments LLC, significantly increased their positions in Natera during the first quarter, indicating strong institutional interest.
• Natera reported a revenue of $546.60 million for the last quarter, exceeding analyst estimates, but posted a loss of ($0.74) earnings per share, missing consensus estimates.

Gordian Capital Singapore Pte Ltd trimmed its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 27.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,450 shares of the medical research company's stock after selling 3,634 shares during the quarter. Natera accounts for approximately 0.8% of Gordian Capital Singapore Pte Ltd's holdings, making the stock its 29th biggest holding. Gordian Capital Singapore Pte Ltd's holdings in Natera were worth $1,360,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fulton Bank N.A. increased its position in shares of Natera by 2.0% during the 1st quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock worth $516,000 after purchasing an additional 71 shares during the last quarter. Compound Planning Inc. increased its position in shares of Natera by 4.2% during the 1st quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company's stock valued at $271,000 after purchasing an additional 78 shares during the period. QRG Capital Management Inc. boosted its position in Natera by 1.5% during the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock valued at $766,000 after purchasing an additional 81 shares during the last quarter. Earned Wealth Advisors LLC raised its stake in shares of Natera by 5.0% in the first quarter. Earned Wealth Advisors LLC now owns 1,737 shares of the medical research company's stock valued at $246,000 after purchasing an additional 82 shares in the last quarter. Finally, Bridges Investment Management Inc. boosted its position in Natera by 5.5% in the 1st quarter. Bridges Investment Management Inc. now owns 1,676 shares of the medical research company's stock valued at $237,000 after buying an additional 87 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Royal Bank Of Canada boosted their price target on Natera from $251.00 to $255.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Morgan Stanley reiterated an "overweight" rating and issued a $195.00 target price on shares of Natera in a research note on Sunday, August 10th. Barclays reissued an "overweight" rating and issued a $210.00 price objective (up from $190.00) on shares of Natera in a research note on Friday, August 8th. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $220.00 target price (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $193.19.

Natera Price Performance

Shares of NTRA stock traded up $1.09 during trading on Tuesday, reaching $169.34. The company had a trading volume of 1,041,812 shares, compared to its average volume of 1,491,737. The company has a market capitalization of $23.24 billion, a PE ratio of -88.66 and a beta of 1.68. Natera, Inc. has a one year low of $110.57 and a one year high of $183.00. The firm's 50 day simple moving average is $154.36 and its two-hundred day simple moving average is $153.77.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same quarter in the previous year, the company posted ($0.30) EPS. Natera's revenue for the quarter was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. Analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Activity

In other Natera news, CFO Michael Burkes Brophy sold 3,045 shares of the firm's stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total value of $418,383.00. Following the completion of the sale, the chief financial officer directly owned 65,430 shares of the company's stock, valued at $8,990,082. This trade represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Gail Boxer Marcus sold 2,496 shares of Natera stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $133.17, for a total value of $332,392.32. Following the sale, the director directly owned 5,763 shares of the company's stock, valued at approximately $767,458.71. This trade represents a 30.22% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 49,594 shares of company stock worth $7,312,528. 5.63% of the stock is owned by insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.